Literature DB >> 15322768

Myocardial metabolism of 123I-BMIPP under low-dose dobutamine infusion: implications for clinical SPECT imaging of ischemic heart disease.

Ryohei Hosokawa1, Ryuji Nohara, Taku Hirai, Yasuhisa Fujibayashi, Masatoshi Fujita, Naoshige Kambara, Muneo Ohba, Eiji Tadamura, Takeshi Kimura, Toru Kita.   

Abstract

PURPOSE: 123I-(p-iodophenyl)-3-(R,S)-methylpentadecanoic acid (123I-BMIPP) is a fatty acid analog for single-photon emission computed tomography (SPECT) imaging that is mainly stored in the triglyceride pool. Low-dose dobutamine infusion has been reported to improve BMIPP uptake in the stunned myocardium, but the mechanism underlying this effect remains unclear. The purpose of this study was therefore to investigate the myocardial metabolism of 123I-BMIPP in the stunned myocardium under low-dose dobutamine infusion, and to elucidate the mechanism by which dobutamine improves BMIPP uptake.
METHODS: Using open-chest dogs, stunned myocardium was induced by occlusion of the left anterior descending artery (LAD) for 30 min, with subsequent reperfusion (ischemia group, n=6). After direct injection of BMIPP into the LAD, myocardial extraction and retention were examined and metabolites evaluated (using high-performance liquid chromatography) during dobutamine infusion. The results in the ischemia group were compared with findings obtained in a control group under dobutamine infusion (n=6).
RESULTS: Dobutamine infusion significantly increased both the rapid extraction (within 30 s) of BMIPP into the myocardium (control vs ischemia group: 48+/-19% vs 66+/-14%, p<0.05) and its subsequent retention (73+/-13% vs 85+/-8%, p<0.05). The metabolites from the myocardium consisted of back diffusion of nonmetabolized BMIPP, the alpha-oxidation metabolite, intermediate metabolites, and the full-oxidation metabolite. Among these metabolites, the full-oxidation metabolite decreased significantly (from 34.0+/-20.0% to 15.8+/-9.3%, p<0.05) in the stunned regions, though back diffusion of nonmetabolized BMIPP increased (from 51.3+/-21.9% to 71.3+/-10.1%, p<0.05).
CONCLUSION: These results indicate that increased uptake of BMIPP in stunned myocardium is mainly due to decreased beta-oxidation in tissue and increased shunt retention of BMIPP in the triglyceride pool, and thereby provide further insight into the pathophysiology of stunned myocardium.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322768     DOI: 10.1007/s00259-004-1622-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  19 in total

1.  Effect of exercise induced hyperlactatemia on the biodistribution and metabolism of iodine-123-15(p-iodophenyl)-3-R,S-methyl pentadecanoic acid in normal volunteers.

Authors:  V Caveliers; F De Geeter; I Pansar; P Dendale; A Bossuyt; P R Franken
Journal:  Eur J Nucl Med       Date:  2000-01

2.  Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography.

Authors:  L A Piérard; C M De Landsheere; C Berthe; P Rigo; H E Kulbertus
Journal:  J Am Coll Cardiol       Date:  1990-04       Impact factor: 24.094

3.  Doppler measurement of myocardial thickening with a single epicardial transducer.

Authors:  C J Hartley; L A Latson; L H Michael; C L Seidel; R M Lewis; M L Entman
Journal:  Am J Physiol       Date:  1983-12

4.  Myocardial kinetics of iodine-123-BMIPP in canine myocardium after regional ischemia and reperfusion: implications for clinical SPECT.

Authors:  R Hosokawa; R Nohara; Y Fujibayashi; K Okuda; M Ogino; T Hata; M Fujita; N Tamaki; J Konishi; S Sasayama
Journal:  J Nucl Med       Date:  1997-12       Impact factor: 10.057

5.  Fatty acid metabolic imaging with iodine-123-BMIPP for the diagnosis of coronary artery disease.

Authors:  S Fujiwara; Y Takeishi; H Atsumi; K Takahashi; H Tomoike
Journal:  J Nucl Med       Date:  1997-02       Impact factor: 10.057

6.  Metabolic fate of iodine-123-BMIPP in canine myocardium after administration of etomoxir.

Authors:  R Hosokawa; R Nohara; Y Fujibayashi; K Okuda; M Ogino; T Hata; M Fujita; N Tamaki; J Konishi; S Sasayama
Journal:  J Nucl Med       Date:  1996-11       Impact factor: 10.057

7.  Abnormal free fatty acid uptake in subacute myocardial infarction after coronary thrombolysis: correlation with wall motion and inotropic reserve.

Authors:  P R Franken; F De Geeter; P Dendale; D Demoor; P Block; A Bossuyt
Journal:  J Nucl Med       Date:  1994-11       Impact factor: 10.057

8.  Effect of oral glucose loading on the biodistribution of BMIPP in normal volunteers.

Authors:  F De Geeter; V Caveliers; I Pansar; A Bossuyt; P R Franken
Journal:  J Nucl Med       Date:  1998-11       Impact factor: 10.057

9.  [Basic studies on I-123-beta-methyl-p-iodophenylpentadecanoic acid (BMIPP) for myocardial functional diagnosis: effect of beta-oxidation inhibitor].

Authors:  Y Fujibayashi; Y Yonekura; K Kawai; K Yamamoto; N Tamaki; J Konishi; A Yokoyama; K Torizuka
Journal:  Kaku Igaku       Date:  1988-10

10.  Evaluation of nonradioactive, colored microspheres for measurement of regional myocardial blood flow in dogs.

Authors:  S L Hale; K J Alker; R A Kloner
Journal:  Circulation       Date:  1988-08       Impact factor: 29.690

View more
  3 in total

1.  The declining prevalence of ST elevation myocardial infarction in patients presenting with acute coronary syndromes.

Authors:  N S Kleiman; H D White
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

Review 2.  Imaging of myocardial fatty acid oxidation.

Authors:  Kieren J Mather; Timothy R DeGrado
Journal:  Biochim Biophys Acta       Date:  2016-02-27

3.  Reduced 123I-BMIPP uptake implies decreased myocardial flow reserve in patients with chronic stable angina.

Authors:  Hiroyuki Kageyama; Koichi Morita; Chietsugu Katoh; Takahiro Tsukamoto; Kazuyuki Noriyasu; Megumi Mabuchi; Masanao Naya; Yuko Kawai; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-23       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.